U.S. markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.42 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.93 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.01 (-0.01%)
     
  • Gold

    1,753.90
    +2.50 (+0.14%)
     
  • Silver

    22.42
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1726
    -0.0046 (-0.39%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3741
    -0.0055 (-0.40%)
     
  • USD/JPY

    109.9210
    +0.2030 (+0.19%)
     
  • BTC-USD

    47,554.02
    -551.21 (-1.15%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.61%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Charles River Laboratories Schedules First-Quarter 2021 Earnings Release and Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

– Virtual Investor Day Scheduled on May 27th

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2021 financial results on Tuesday, May 4th, before the market opens. A conference call has been scheduled to discuss this information on Tuesday, May 4th, at 9:00 a.m. ET.

Investor Day

Charles River will also host a virtual Meeting with Management on Thursday, May 27th, starting at 8:30 a.m. ET. The virtual event will feature presentations from Charles River’s senior management team, including an overview of its strategic focus, business developments, and updated financial targets.

Investors and the general public will have the opportunity to listen to webcasts of the earnings conference call and the Investor Day event through a link that will be posted on the Investor Relations section of the Company's website at ir.criver.com. Webcast replays will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005190/en/

Contacts

Investor Relations:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com